GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LUMOSA THERAPEUTICS CO LTD (ROCO:6535) » Definitions » Valuation Rank

LUMOSA THERAPEUTICS CO (ROCO:6535) Valuation Rank


View and export this data going back to 2015. Start your Free Trial

What is LUMOSA THERAPEUTICS CO Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

LUMOSA THERAPEUTICS CO Valuation Rank Related Terms

Thank you for viewing the detailed overview of LUMOSA THERAPEUTICS CO's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

LUMOSA THERAPEUTICS CO (ROCO:6535) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LUMOSA THERAPEUTICS CO LTD (ROCO:6535) » Definitions » Valuation Rank
Comparable Companies
ROCO:6875 TPE:6541 TPE:1760 ROCO:6696 ROCO:4157 ROCO:4728 ROCO:6885 ROCO:4726 ROCO:6838 ROCO:3176 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Yuanyuan Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
Website
https://www.lumosa.com.tw
LUMOSA THERAPEUTICS CO LTD develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of CNS, oncology, and inflammatory diseases. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan and America. Its product portfolio includes LT - 1001 and LT - 3001 for Analgesic Injection and Novel Small Molecules for the Treatment of Acute Ischemic Stroke.